

# Table of Contents

<b>1</b>	<b>Introduction .....</b>	<b>7</b>
1.1	Overview .....	7
1.2	Purpose .....	7
1.3	Scope .....	7
1.4	Benefits .....	8
1.5	Objective .....	8
1.6	Structure .....	8
1.7	Key Concepts .....	9
<b>2</b>	<b>Definition and Types of Biologics .....</b>	<b>11</b>
<b>3</b>	<b>Biopharmaceutical Product Development for Recombinant Therapeutic Bioproducts .....</b>	<b>13</b>
3.1	Project Management and Planning .....	13
3.1.1	Project Planning Tools .....	13
3.2	Development Phases .....	17
3.2.1	Preclinical Phases .....	17
3.2.2	Clinical Phases .....	18
3.2.3	Comparability and Bridging .....	20
<b>4</b>	<b>Process Development and Manufacturing Considerations for Recombinant Therapeutic Bioproducts .....</b>	<b>23</b>
4.1	Introduction .....	23
4.1.1	Expression System Development/Cell Line Development .....	23
4.1.2	Product Expression (Cell Culture/Fermentation) .....	28
4.1.3	Cell Separation .....	33
4.1.4	Purification Process Development .....	36
4.1.5	Bulk Storage Issues/Considerations .....	46
4.2	Drug Product (DP) Process Development .....	48
4.2.1	Drug Product Formulation and Process Development .....	48
4.2.2	Stability: Container Closure and Extractables .....	49
4.3	Manufacture of Drug Substance (DS) .....	51
4.3.1	Cell Banks .....	51
4.3.2	Raw Material Considerations .....	51
4.3.3	Facility Considerations .....	53
4.4	Process Validation .....	55
4.5	Drug Product Manufacturing .....	56
4.5.1	Raw Material Considerations .....	56
4.5.2	Process Equipment Design and Selection .....	56
4.5.3	Typical Drug Product Manufacturing Steps .....	58
4.5.4	Parenteral Facilities .....	59

<b>5</b>	<b>Supply Chain Management of Biological Investigational Products for Clinical Trials .....</b>	<b>63</b>
5.1	Introduction .....	63
5.2	Complexities in the Clinical Supply Chain .....	66
5.2.1	Safety .....	67
5.2.2	Supply Limitations .....	67
5.2.3	Lot Sizes .....	67
5.2.4	Strategies for Conserving Product .....	67
5.2.5	Blinding .....	69
5.2.6	Sampling .....	69
5.2.7	Analytical Testing and Product Release Considerations .....	69
5.2.8	Stability and Shelf Life .....	69
5.2.9	Storage and Handling .....	70
5.2.10	Labeling .....	71
5.2.11	Shipping .....	72
<b>6</b>	<b>Quality Control and Quality Assurance Considerations .....</b>	<b>73</b>
6.1	Analytical Methods Qualification/Validation Strategies .....	73
6.2	Document Generation, Review, Approval System .....	74
6.3	Drug Substance (DS) and Drug Product (DP) Release Considerations .....	74
6.3.1	Batch Record and Associated Document Review .....	75
6.3.2	DS and DP as Filed Release Testing in IND .....	75
6.4	Product Quality and Stability Requirements .....	75
<b>7</b>	<b>Global Regulatory Strategies .....</b>	<b>77</b>
7.1	US Considerations .....	77
7.2	European Considerations .....	79
7.3	Canada .....	79
7.4	Japan .....	79
7.5	ICH Guidelines .....	79
7.6	Importation/Exportation .....	80
<b>8</b>	<b>Glossary .....</b>	<b>81</b>
8.1	Definitions .....	81
8.2	Acronyms and Abbreviations .....	81
<b>9</b>	<b>References .....</b>	<b>83</b>